Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Flortaucipir and Neuroinflammation PET in Semantic Dementia
Aging, Dementia, and Behavioral Neurology
P10 - Poster Session 10 (5:30 PM-6:30 PM)
10-002
We studied whether there was an association between flortaucipir ([18F]AV-1451) uptake and neuroinflammation, measured with the TSPO tracer 11C-PBR28.
Semantic dementia (SD) is typically associated with TDP-43-positive neuropil threads and dystrophic neuritis (type C), very seldom with tau. However patients with SD show elevated uptake of the tau PET tracer flortaucipir  in anterior temporal regions. This uptake could be related to non-specific binding, perhaps caused by inflammation, as SD is associated with a propensity for autoimmune disease and increased inflammation in peripheral blood.

Six SD patients, all PET amyloid-negative, had 11C-PBR28 and flortaucipir PET. Fourteen healthy controls underwent 11C-PBR28 PET (n=6) or flortaucipir PET (n=8). Patients (4/6 women, mean age 69±8.5 years) did not differ significantly in age from the controls (5/14 women, mean age 69±6.7 years). The VT values for 11C-PBR28 were calculated at the regional and voxel levels using a Logan plot and a metabolite-corrected arterial input function. The SUV ratio over the cerebellar gray matter for flortaucipir was calculated for t = 80-100 min.  
Compared to controls, patients showed increased VT and SUVr values in left temporal regions, and in anterior right temporal lobe, as well as in regions of the orbitofrontal cortex adjoining anterior temporal cortex and insular cortex. However the peaks for flortaucipir and 11C-PBR28 VT did not coincide, inflammation being greatest posterior to the flortaucipir peak in left temporal pole.

Neuroinflammation was greatest at the margin of progression of the disease. Our findings leave the door open for neurobiological processes other than inflammation to explain increased flortaucipir uptake in the temporal pole in semantic dementia.

Authors/Disclosures
Joseph C. Masdeu, MD, PhD, FÂ鶹´«Ã½Ó³»­ (Houston Methodist Neurological Institute)
PRESENTER 		Dr. Masdeu has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lilly . The institution of Dr. Masdeu has received research support from NIH. The institution of Dr. Masdeu has received research support from Houston Methodist Foundation. The institution of Dr. Masdeu has received research support from Alector. The institution of Dr. Masdeu has received research support from Aviado-Bio. Dr. Masdeu has received publishing royalties from a publication relating to health care. Dr. Masdeu has received publishing royalties from a publication relating to health care. Dr. Masdeu has received personal compensation in the range of $100,000-$499,999 for serving as a Director, Nantz Nal Alzheimer Center with HOUSTON METHODIST NEUROLOGICAL INSTITUTE.
Belen Pascual, PhD (Houston Methodist Hospital) The institution of Prof. Pascual has received research support from NIH. The institution of Prof. Pascual has received research support from NIH.
No disclosure on file
No disclosure on file
Quentin Funk Quentin Funk has nothing to disclose.
Meixiang Yu No disclosure on file
Paul E. Schulz, MD (UT Physicians) Dr. Schulz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisa .
Gustavo C. Roman, MD, FÂ鶹´«Ã½Ó³»­ (Methodist Neurological Institute) The institution of Dr. Roman has received research support from Brain Chamistry Labs.
Paolo Zanotti Fregonara Paolo Zanotti Fregonara has nothing to disclose.